Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal

Takahiro Suzuki, Kenji Hayakawa, Yoshihiro Nakagawa, Hiromi Onouchi, Masafumi Ogata, Kenji KawaiDepartment of Ophthalmology, Tokai University School of Medicine, Isehara, JapanBackground: The purpose of this study was to evaluate prospectively the efficacy of a topical carbonic anhydrase inhibitor i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Suzuki T, Hayakawa K, Nakagawa Y, Onouchi H, Ogata M, Kawai K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/8862b97747ef422a82c9bc78f1af123f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8862b97747ef422a82c9bc78f1af123f
record_format	dspace
spelling	oai:doaj.org-article:8862b97747ef422a82c9bc78f1af123f2021-12-02T09:19:11ZTopical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal1177-54671177-5483https://doaj.org/article/8862b97747ef422a82c9bc78f1af123f2013-04-01T00:00:00Zhttp://www.dovepress.com/topical-dorzolamide-for-macular-edema-in-the-early-phase-after-vitrect-a12832https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Takahiro Suzuki, Kenji Hayakawa, Yoshihiro Nakagawa, Hiromi Onouchi, Masafumi Ogata, Kenji KawaiDepartment of Ophthalmology, Tokai University School of Medicine, Isehara, JapanBackground: The purpose of this study was to evaluate prospectively the efficacy of a topical carbonic anhydrase inhibitor in macular edema after vitrectomy.Methods: Forty patients were included, all of whom had undergone vitrectomy combined with phacoemulsification and intraocular lens implantation for epiretinal membrane. Twenty eyes from 40 patients received topical 2% dorzolamide three times a day. The patients were followed up for at least 3 months. In this study, we evaluated the effect of dorzolamide on visual acuity, intraocular pressure, central macular thickness, and aqueous flare.Results: Mean logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity preoperatively and 2 weeks, 1 month, and 3 months after surgery was 0.48 ± 0.23, 0.60 ± 0.16, 0.40 ± 0.29, and 0.24 ± 0.32, respectively, in the treatment group, and 0.40 ± 0.09, 0.44 ± 0.12, 0.32 ± 0.10, and 0.16 ± 0.09, respectively, in the control group. No statistically significant difference was observed between the two groups. Mean central macular thickness preoperatively and at 2 weeks and 3 months after surgery was 572.6, 427.2, and 333.4 µm, respectively, in the treatment group, and 571.4, 485.2, and 388.4 µm, respectively, in the control group. Mean aqueous flare preoperatively, and 1 month and 3 months after surgery was 8.6, 34.2, and 23.5 photon counts per millisecond (pc/ms), respectively, in the treatment group, and 9.7, 24.7, and 23.4 pc/ms, respectively, in the control group. No statistically significant differences were observed between data from the two groups. However, statistically significant (P < 0.05) differences in mean central macular thickness at 1 month and mean aqueous flare at 2 weeks after surgery were found between the treatment group (358.8 µm, 36.8 pc/ms) and the control group (467.8 µm, 64.0 pc/ms). Differences in mean intraocular pressure preoperatively and at 2 weeks, 1 month, and 3 months after surgery were not statistically significant between the two groups. Intraocular pressure never exceeded 21 mmHg.Conclusion: Topical dorzolamide significantly reduced mean central macular thickness at 1 month and mean aqueous flare at 2 weeks after surgery for epiretinal membrane compared with controls. Although further investigation of more cases and longer follow-up are needed, this study suggests that topical dorzolamide can be efficacious in reducing macular edema in the early phase after vitrectomy via its anti-inflammatory effect.Keywords: macular edema, dorzolamide, epiretinal membrane, vitrectomy, anti-inflammatorySuzuki THayakawa KNakagawa YOnouchi HOgata MKawai KDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 549-553 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Suzuki T Hayakawa K Nakagawa Y Onouchi H Ogata M Kawai K Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal
description	Takahiro Suzuki, Kenji Hayakawa, Yoshihiro Nakagawa, Hiromi Onouchi, Masafumi Ogata, Kenji KawaiDepartment of Ophthalmology, Tokai University School of Medicine, Isehara, JapanBackground: The purpose of this study was to evaluate prospectively the efficacy of a topical carbonic anhydrase inhibitor in macular edema after vitrectomy.Methods: Forty patients were included, all of whom had undergone vitrectomy combined with phacoemulsification and intraocular lens implantation for epiretinal membrane. Twenty eyes from 40 patients received topical 2% dorzolamide three times a day. The patients were followed up for at least 3 months. In this study, we evaluated the effect of dorzolamide on visual acuity, intraocular pressure, central macular thickness, and aqueous flare.Results: Mean logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity preoperatively and 2 weeks, 1 month, and 3 months after surgery was 0.48 ± 0.23, 0.60 ± 0.16, 0.40 ± 0.29, and 0.24 ± 0.32, respectively, in the treatment group, and 0.40 ± 0.09, 0.44 ± 0.12, 0.32 ± 0.10, and 0.16 ± 0.09, respectively, in the control group. No statistically significant difference was observed between the two groups. Mean central macular thickness preoperatively and at 2 weeks and 3 months after surgery was 572.6, 427.2, and 333.4 µm, respectively, in the treatment group, and 571.4, 485.2, and 388.4 µm, respectively, in the control group. Mean aqueous flare preoperatively, and 1 month and 3 months after surgery was 8.6, 34.2, and 23.5 photon counts per millisecond (pc/ms), respectively, in the treatment group, and 9.7, 24.7, and 23.4 pc/ms, respectively, in the control group. No statistically significant differences were observed between data from the two groups. However, statistically significant (P < 0.05) differences in mean central macular thickness at 1 month and mean aqueous flare at 2 weeks after surgery were found between the treatment group (358.8 µm, 36.8 pc/ms) and the control group (467.8 µm, 64.0 pc/ms). Differences in mean intraocular pressure preoperatively and at 2 weeks, 1 month, and 3 months after surgery were not statistically significant between the two groups. Intraocular pressure never exceeded 21 mmHg.Conclusion: Topical dorzolamide significantly reduced mean central macular thickness at 1 month and mean aqueous flare at 2 weeks after surgery for epiretinal membrane compared with controls. Although further investigation of more cases and longer follow-up are needed, this study suggests that topical dorzolamide can be efficacious in reducing macular edema in the early phase after vitrectomy via its anti-inflammatory effect.Keywords: macular edema, dorzolamide, epiretinal membrane, vitrectomy, anti-inflammatory
format	article
author	Suzuki T Hayakawa K Nakagawa Y Onouchi H Ogata M Kawai K
author_facet	Suzuki T Hayakawa K Nakagawa Y Onouchi H Ogata M Kawai K
author_sort	Suzuki T
title	Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal
title_short	Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal
title_full	Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal
title_fullStr	Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal
title_full_unstemmed	Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal
title_sort	topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/8862b97747ef422a82c9bc78f1af123f
work_keys_str_mv	AT suzukit topicaldorzolamideformacularedemaintheearlyphaseaftervitrectomyandepiretinalmembraneremoval AT hayakawak topicaldorzolamideformacularedemaintheearlyphaseaftervitrectomyandepiretinalmembraneremoval AT nakagaway topicaldorzolamideformacularedemaintheearlyphaseaftervitrectomyandepiretinalmembraneremoval AT onouchih topicaldorzolamideformacularedemaintheearlyphaseaftervitrectomyandepiretinalmembraneremoval AT ogatam topicaldorzolamideformacularedemaintheearlyphaseaftervitrectomyandepiretinalmembraneremoval AT kawaik topicaldorzolamideformacularedemaintheearlyphaseaftervitrectomyandepiretinalmembraneremoval
_version_	1718398133360132096

Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal

Ejemplares similares